Language: BG BG
← Back to results
Active (not recruiting) Not applicable NCT05871502

Glycemia and Ischemia Reperfusion Brain Injury in Patients With Acute Cerebral Infarction Treated With Mechanical Thrombectomy

No applicable phase (e.g. observational)
Conditions: Cerebral Infarction

Sponsor: Instituto de Investigación Hospital Universitario La Paz

trial.available_in: БГ
Overview
Postictus hyperglycemia is associated with an accelerated transformation of the ischemic penumbra into an infarct area, with increased infarct size, worse recanalization, reduced cerebral perfusion, increased ischemia reperfusion damage, and worse outcome. Furthermore, when perfusion is reinstated, hyperglycemia causes secondary tissue damage through an increase in ischemic reperfusion damage. Thus, those patients with glycemia values \< 155 mg/dL during mechanical thrombectomy, and especially at the time of reperfusion, will have greater ischemia-reperfusion damage, showing a different profile in miRNA expression, with better neurological and functional outcomes and higher risk of hemorrhagic transformation and cerebral edema. The main objective of the study is to evaluate the association between glycemia values at the time of reperfusion and stroke recovery at 3 months in patients with acute cerebral infarction treated with mechanical thrombectomy.
Who can participate
Inclusion Criteria: * Men and women over 18 years of age * Neuroimaging studies such as computed tomography (CT), angio-CT or angio-MRI compatible with the diagnosis of acute cerebral infarction due to occlusion of a large vessel of the anterior circulation, including the internal carotid artery (intra- or extracranial) or middle cerebral artery (M1 or M2 segments). * Indication of mechanical thrombectomy according to clinical practice. * Inclusion of the patient in the study before the endovascular procedure. * Modified Rankin Scale (mRS) score prior to stroke of 0-1. * Signature of informed consent. Exclusion Criteria: * CT, angio-CT or angio-MRI showing posterior circulation occlusion. * Severe or life-threatening concomitant disease that precludes follow-up for 3 months after stroke, * Alcohol or drug abuse * Participation in a therapeutic clinical trial.
Interventions
Subcutaneous blood glucose monitoring device
DEVICE
Locations 1
Spain (1)
Hospital Universitario La Paz
Madrid
Technical details
Status
Active (not recruiting)
Phase
Not applicable
Study type
INTERVENTIONAL
Sex
Male and female
Minimum age
18 Years
Healthy volunteers
No
Start date
13.04.2023
Completion date
15.07.2026
Registry ID
NCT05871502
Source
clinicaltrials.gov
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.